The work aimed to investigate the biochemical changes in serum sFas/sFasL system and its usefulness as an apoptogenic markers in patients with Bilharzial fibrosis, liver cirrhosis (LC) with and without hepatocellular carcinoma (HCC).
The study was carried on 50 subjects; 10 as control group and 40 patients; 15 patients with Bilharzial hepatic fibrosis (BHF), 15 patients suffering from liver cirrhosis on top of HCV and 10 patients with Hepatocellular carcinoma (HCC) selected from Gastroenterology department at Benha University Hospital. After complete history taking, full clinical examination and laboratory investigations for estimation of serum liver function tests, sFas and sFasL
Serum sFas was significantly elevated (P0.05) compared with the control group with a positive non-significant correlation between serum sFas and liver function tests, serum AFP and sFasL in patients with Bilharzial hepatic fibrosis.
Serum levels of sFas and sFasL were significantly elevated in patients with liver cirrhosis due to HCV infection compared with the control group (P |
